The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease

European Journal of Neurology

Volumn 12, Issue 1, 2005, Pages 49-54

  Bartosik Psujek, Halina ^a   Stelmasiak, Z ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CCL2; CCL5; Chemokines; CXCL8; Multiple sclerosis

Indexed keywords

CHEMOKINE; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE;

ADULT; CHEMOKINE CCL2; CHEMOKINES, CC; HUMANS; INTERLEUKIN-8; MIDDLE AGED; MULTIPLE SCLEROSIS; STATISTICS, NONPARAMETRIC;

EID: 12744274563     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00951.x     Document Type: Article

References (23)

1. Andersson M, Alvarez-Cermeno J, Bernardi G et al. (1994). Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897-902.
2. Baggiolini M (1998). Chemokines and leukocyte traffic. Nature 392:565-568.
3. Franciotta D, Martino G, Zardini E et al. (2001). Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115:192-198.
4. Glabinski AR, Bielecki B, Ransohoff RM (2003). Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol 58:81-88.
5. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins B (2000). Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411.
6. Iarlori C, Reale M, Lugaresi A et al. (2000). RANTES production and expression is reduced in relapsing-remitting multiple sclerosis treated with interferon β-1b. J Neuroimmunol 107:100-107.
7. Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I (2002). Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. J Neurol 249:576-583.
8. Karpus WJ, Kennedy KJ (1997). MIP-1 alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62:681-687.
9. Luster A (1998). Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445.
10. Mahad DJ, Howell SJL, Woodroofe MN (2002). Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72:498-502.
11. Martinez-Caceres EM, Espejo C, Brieva L et al. (2002). Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult Scler 8:390-395.
12. Moser B, Loetscher P (2001). Lymphocyte traffic control by chemokines. Nat Immunol 2:123-128.
13. Olsson T (1995). Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in EAE and multiple sclerosis. Immunol Rev 144:245-268.
14. Opdenakker G, Nelissen I, Van Damme J (2003). Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2:747-756.
15. Poser CM, Paty DW, Scheinberg L et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
16. Schumacher GA (1974). Critique of experimental trials of therapy in multiple sclerosis. Neurology 24:1010-1014.
17. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN (1998). Expression of monocyte chemoattractant protein-1 and other β chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238-249.
18. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP (2001). Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 104:88-91.
19. Sørensen TL, Tani M, Jensen J et al. (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815.
20. Sørensen TL, Sellebjerg F, Jensen J, Strieter RM, Ransohoff R (2001). Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 8:665-672.
21. Traboulsee A, Dehmeshki J, Peters KR et al. (2003). Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 9:566-573.
22. Trapp BD, Bö L, Mörk S, Chang A (1998). Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98:49-56.
23. Zlotnik A, Yoshie O (2000). Chemokines: a new classification system and their role in immunity. Immunity 2:121-127.